GLYCOSYL FERASE HIBITORS
DE602019083660T2Active Publication Date: 2026-04-15CALIFORNIA INST OF TECH +1
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- CALIFORNIA INST OF TECH
- Filing Date
- 2019-01-11
- Publication Date
- 2026-04-15
AI Technical Summary
Technical Problem
There is a need for structurally diverse and potent DPAGT1 inhibitors to treat bacterial infections and cancer, as current inhibitors face challenges in selectivity and cytotoxicity.
Method used
Development of compounds of Formula I and their pharmaceutically acceptable salts, which inhibit DPAGT1, including specific combinations with other therapeutic agents like taxol, tunicamycin, and gemcitabine, for treating infections and cancers by targeting the first committed enzyme in N-glycan biosynthesis.
Benefits of technology
The compounds effectively inhibit DPAGT1, offering therapeutic potential for treating bacterial infections such as Clostridium difficile and various cancers by reducing cytotoxicity and enhancing treatment efficacy through synergistic effects.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.